Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study

Muñoz, F. Longo; Fernández, Mónica Jorge; Tur, R. Yaya; Díaz, Silvia; Ortega, María Eugenia; Dilla, Tatiana; Molero, A.; Cervera, Jose Manuel

doi:10.1093/annonc/mdz247.119

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety and effectiveness of ramucirumab as a treatment option for patients with GC/GEJ adenocarcinoma has also been examined in real world clinical practice in the Western world. For example, in the RAMIS study in Spain [ 68 ], the RAMOSS study in Italy [ 69 ], along with a few smaller studies [ 70 , 71 , 72 , 73 ], all indicated that ramucirumab is well tolerated in real life situations with similar survival outcomes and response rates as seen in the RCTs.…”

Section: Resultsmentioning

confidence: 99%

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

GI cancers are characterized by high recurrence rates and a dismal prognosis and there is an urgent need for new therapeutic approaches. This is a narrative review designed to provide a summary of the efficacy as measured by overall survival, progression free survival, and safety data from phase 3 randomized controlled GI clinical trials of ramucirumab including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Quality of life (QOL) is discussed where data are available. Our aim was to summarize the efficacy and safety of ramucirumab in the treatment of GI cancers using these existing published data with a view to demonstrating how ramucirumab may help improve treatment outcome for patients with GI cancers. The data indicate that ramucirumab is efficacious, safe, and tolerable across the intent-to-treat patient populations as a whole and across several pre-specified subgroups, even those whose disease is traditionally more difficult to treat. Furthermore, survival outcomes observed in real-world clinical practice demonstrate similar data from phase 3 clinical trials even in patients with complications, suggesting that the benefits of ramucirumab translate in actual clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study

Cited by 1 publication

References 0 publications

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?

Contact Info

Product

Resources

About